CDC 3-14-11
Abstract
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
Source
http://www.sfgate.com/
Date of Publication
03/09/2011
Author
Kristen Hallam, Bloomberg News
Article Type
General media
Article Category
News Briefs
Source
No comments:
Post a Comment